Frontlight ResearchEarly access
Taking people in United StatesPhase 2
Repurposing Insulin With Intranasal Administration to Improve Function After Mild Traumatic Brain Injury
Key facts
- Who runs it
- HealthPartners Institute
- Where
- Saint Paul, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 96 people, planned
- Started
- Nov 2026
- Expected to end
- Dec 2027
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Insulin (Humulin)
- Placebo
- Record updated
- 13 November 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Subject has presented to a clinic/ER reporting an acute head injury (e.g., a closed head injury or blunt TBI) and presents with at least two symptoms of TBI, as defined by the listed symptoms on the Post-Concussion Symptom Scale (PCSS)
- Subject is considered high risk for persistent post-concussion symptoms using the post-concussion symptom (PoCS) clinical decision rule
- Subject is between ≥18 and ≤65 years of age
- Treatment can be initiated within 5-14 days after injury, inclusive
- Subject must be proficient in speaking English in order to comply with instructions and measures for the study
- Subject must be able to consent
- Female subjects of childbearing potential must have a negative pregnancy test at the baseline visit and be willing to use a medically acceptable contraceptive method for the duration of the study
Who cannot take part
- Subjects has received an intranasal vaccine within 2 weeks of the date of their baseline visit
- Subject has medical history and/or clinically determined disorders: chronic sinusitis, previous nasal and/or oto-pharyngeal surgery, and severe deviated septum and/or other anomalies, including findings of an abnormal nasopharyngeal exam that could interfere with intranasal administration as judged by the PI, e.g., inflammation, erythema, bleeding, atrophy, septal perforation, mucosal erosion, localized infection or ulceration, polyposis
- Subject has participated in a clinical trial investigation (drug or device) within 3 months of this study
- Subject has evidence of acute intracranial hemorrhage at screening
- Subject has history of any of the following: active and significant central nervous system, psychiatric illness, pulmonary, or cardiovascular disorders or any other clinically relevant abnormality that inclusion would pose a safety risk to the subject as determined by investigator
- Subject has an insulin allergy
- Subject is taking insulin for Type I or Type II diabetes
- Subject's concussion or TBI resulted in loss of consciousness of > 30 minutes
- Subject has evidence of blast injury, electrocution injury, or significant multisystem trauma associated with the mTBI, including significant nasal trauma
- Subject is pregnant or breast feeding
- Subjects with nasal piercings or any physical finding in the nose that, in the opinion of the PI, would be likely to interfere with successful completion of dosing
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
This trial is currently available in United States.
- HealthPartners Neuroscience CenterSaint Paul, United StatesContact: Clinical Trial CoordinatorTaking people
About the trial
What the trial wants to find out
This Phase II clinical trial protocol will provide evidence as to whether IN insulin is efficacious in reducing symptoms in people seeking care for mild TBI (concussion).
The 3 groups in the trial
- Dose 1 - 40 IU/IN (20 IU, twice daily x 21 days)Treatment being tested
Intranasal insulin, lower dose, 40 IU insulin, twice daily for 21 days
Treatment: Insulin (Humulin)
- Dose 2 - 80 IU/IN (40 IU, twice daily x 21 days)Treatment being tested
Intranasal insulin, higher dose, 80 IU insulin, twice daily for 21 days
Treatment: Insulin (Humulin)
- Dose 3 - PlaceboPlacebo, for comparison
intranasal, twice daily for 21 days
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT07935278, who can take part
- Record updated
- 13 November 2026